NCT06258642 2025-08-20
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Fudan University
Phase NA Recruiting
Clinical Trials
8 trialsNCT07004712 2025-06-08
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06749691 2024-12-27
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06739928 2024-12-18
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 2 Recruiting
NCT05049863 2024-12-05
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Washington University School of Medicine
Phase 1 Terminated
NCT06478043 2024-07-08
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06332950 2024-03-27
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT04088786 2022-05-06
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
Phase 1 Completed